Transdermal Delivery Solutions and MHC Medical Products announce license for Penetran+Plus topical pain reliever
With the acquisition of Penetran-Plus, MHC expands into the OTC pain relief market.
Transdermal Delivery Solutions Corporation (TDSC), a developer of spray-on drug delivery systems, has signed a product license arrangement with MHC Medical Products, of Cincinnati, OH — a rapidly growing consumer healthcare company.
"We are pleased to announce the finalization of our agreement for this first product with the team at MHC,” said Kenneth Kirby, President of TDSC. “MHC is the manufacturer of one of the country’s fastest growing lines of branded medical devices and other consumer healthcare products including the EasyTouch brand of insulin syringes and blood glucose meters, HealthPro blood glucose meters, and SureLife blood pressure monitors.” With the acquisition of Penetran-Plus, MHC is expanding into the over-the-counter pain relief market.
Up until this time, Penetran+Plus had limited regional distribution. “We are pleased and honored to have the MHC team acquire the product license and expand the distribution,” said Kirby. Penetran+Plus is a topical analgesic gel that is marketed as an over-the-counter remedy for temporary relief of minor aches and pains, bruises and strains. The product was designed with a pleasant natural lemon oil fragrance, a non-sticky formula and has been successfully tested for pains associated with arthritis in a double blind study against placebo which was published in a peer-reviewed journal. The product label has been reviewed by the FDA Center for Drug Evaluation and Research Office of Unapproved Drugs and Labeling Compliance (OUDLC), Over the Counter Branch and found to be in compliance with the OTC Monograph for Topical Pain Relief.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance